Urolithiasis is a common and complex disease of the urinary system, which can cause urinary tract blockage, urinary tract infection, and even damage to urinary system-related tissues. Although urolithiasis can be cure...Urolithiasis is a common and complex disease of the urinary system, which can cause urinary tract blockage, urinary tract infection, and even damage to urinary system-related tissues. Although urolithiasis can be cured, its high recurrence rate and the development of chronic kidney disease in some patients have drawn the attention of nephrologists. Although the application of extracorporeal lithotripsy, percutaneous nephrolithotomy and other minimally invasive techniques have made the treatment of urolithiasis more efficient, pharmacotherapy plays an indispensable role in reducing their morbidity and recurrence rates. Traditional Chinese medicine(TCM) has been used for treatment and prevention of urolithiasis in developing countries for centuries, known for its unquestionable efficacy and safety. This article reviews the progress of clinical trials and pharmacological studies on the treatment of urolithiasis with Chinese herbal medicines(CHMs). The mechanism of CHMs in the treatment of urolithiasis mainly involve preventing further growth and aggregation of urolithiasis, reducing the PH of urine, promoting calculus dissolution. Furthermore, some CHMs can increase urine output, relax smooth muscles, and promote the removal of calculus. These findings provide new treatment strategies and options for urolithiasis and secondary kidney damage.展开更多
The cDNA chimeras between two subtypes of mouse excitatory amino acid transporter family, mouse excitatory amino acid carrier 1 （mEAAC1） and mouse alanine serine cysteine transporter 1 （mASCT1）, were constructed b...The cDNA chimeras between two subtypes of mouse excitatory amino acid transporter family, mouse excitatory amino acid carrier 1 （mEAAC1） and mouse alanine serine cysteine transporter 1 （mASCT1）, were constructed by recombinant PCR. After transcription in vitro, the cRNA was injected and expressed in Xenopus laevis oocytes. <sup>3</sup>H-Glu and <sup>3</sup>H-Ser were used as isotopic tracer to measure the flux of amino acids. The results showed that there might not be the key amino acids responsible for substractive specificity in the NH<sub>2</sub>-terminal and its adjacent regions of these two transporters, which probably supported the formation of the substrata binding sites.展开更多
基金supported by Tianjin Municipal Health and Health Committee High-level Talent Project (No. TJSQNYXXR-D2138)。
文摘Urolithiasis is a common and complex disease of the urinary system, which can cause urinary tract blockage, urinary tract infection, and even damage to urinary system-related tissues. Although urolithiasis can be cured, its high recurrence rate and the development of chronic kidney disease in some patients have drawn the attention of nephrologists. Although the application of extracorporeal lithotripsy, percutaneous nephrolithotomy and other minimally invasive techniques have made the treatment of urolithiasis more efficient, pharmacotherapy plays an indispensable role in reducing their morbidity and recurrence rates. Traditional Chinese medicine(TCM) has been used for treatment and prevention of urolithiasis in developing countries for centuries, known for its unquestionable efficacy and safety. This article reviews the progress of clinical trials and pharmacological studies on the treatment of urolithiasis with Chinese herbal medicines(CHMs). The mechanism of CHMs in the treatment of urolithiasis mainly involve preventing further growth and aggregation of urolithiasis, reducing the PH of urine, promoting calculus dissolution. Furthermore, some CHMs can increase urine output, relax smooth muscles, and promote the removal of calculus. These findings provide new treatment strategies and options for urolithiasis and secondary kidney damage.
文摘The cDNA chimeras between two subtypes of mouse excitatory amino acid transporter family, mouse excitatory amino acid carrier 1 （mEAAC1） and mouse alanine serine cysteine transporter 1 （mASCT1）, were constructed by recombinant PCR. After transcription in vitro, the cRNA was injected and expressed in Xenopus laevis oocytes. <sup>3</sup>H-Glu and <sup>3</sup>H-Ser were used as isotopic tracer to measure the flux of amino acids. The results showed that there might not be the key amino acids responsible for substractive specificity in the NH<sub>2</sub>-terminal and its adjacent regions of these two transporters, which probably supported the formation of the substrata binding sites.
